Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), a Calgary-based preclinical biotechnology company, has announced a brokered private placement of units priced at $0.15 each, targeting gross proceeds of between $1,500,000 and $3,000,000. The offering follows prior announcements made on July 16, August 19, and September 9, 2026, and represents a key financing step for the company's drug redevelopment programme. Investors are watching the placement closely given its direct link to funding clinical advancement of the company's lead compound, MB-204.

Key Points

  • Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) is a Calgary-based preclinical biotechnology company focused on synthetic chemical derivatives of known, off-patent drugs.
  • The company is conducting a private placement of units at $0.15 per unit, with a minimum of 10,000,000 units ($1,500,000 gross) and a maximum of 20,000,000 units ($3,000,000 gross).
  • Net proceeds are earmarked for a Phase 1 clinical trial deposit for lead compound MB-204, general and administrative expenses, and working capital.
  • The first closing tranche is targeted for on or around September 30, 2026, subject to TSX Venture Exchange approval.

Unit Structure and Warrant Acceleration Terms for the MRVL Placement

Each unit offered under the placement consists of one common share and one common share purchase warrant. Each warrant entitles the holder to acquire one additional common share at $0.20, exercisable beginning 61 days after the closing date and for a period of one year from closing. The company retains the right to accelerate warrant expiry if the volume-weighted average price of common shares on the TSX Venture Exchange equals or exceeds $0.25 for five consecutive trading days after the 61-day period, provided at least 30 days' written notice is given to warrant holders.

MB-204 Phase 1 Clinical Trial Deposit Among Primary Uses of Proceeds

Marvel Biosciences has stated that net proceeds from the financing will be directed primarily toward a deposit for Phase 1 clinical trials of its lead compound, MB-204. The company's drug redevelopment model involves developing synthetic chemical derivatives of previously approved, off-patent drugs and seeking new patent protection for novel therapeutic indications. Marvel's pipeline targets the adenosine A2A receptor, with applications disclosed across neurological conditions — including depression, anxiety, Alzheimer's disease, and ADHD — as well as cancer and non-alcoholic steatohepatitis.

Finder Fees, Regulatory Approvals, and TSXV Extension

The company may pay finders a cash fee of up to 7% of gross proceeds raised through introduced subscribers, along with finder warrants equal to 7% of the total units subscribed by those investors, exercisable at $0.20 per share on the same terms as investor warrants. The TSX Venture Exchange has approved an extension of the final closing documentation deadline from September 14, 2026 to September 30, 2026. The placement remains subject to all applicable regulatory approvals, and the company notes it may close in one or more tranches.